Article Text
Abstract
Using data obtained during a retrospective interview study of 30 women who had undergone genetic testing—BRCA1/2 mutation searching—this paper describes how women, previously diagnosed with breast/ovarian cancer, perceive their role in generating genetic information about themselves and their families. It observes that when describing their motivations for undergoing DNA testing and their experiences of disclosing genetic information within the family these women provide care based ethical justifications for their actions. Finally, it argues that generating genetic information and disclosing this information to kin raise different types of ethical issues. The implications of these findings for ethical debates about informed choice in the context of genetic testing are discussed.
- BRCA1
- 2 testing
- mutation searching
- care based ethics
- qualitative study
- informed consent
Statistics from Altmetric.com
Footnotes
Read the full text or download the PDF:
Other content recommended for you
- The impact of proband mediated information dissemination in families with a BRCA1/2 gene mutation
- Challenges of genetic testing in adolescents with cardiac arrhythmia syndromes
- Anticipated health behaviour changes and perceived control in response to disclosure of genetic risk of breast and ovarian cancer: a quantitative survey study among women in the UK
- An evaluation of needs of female BRCA1and BRCA2 carriers undergoing genetic counselling
- The right not to know: an autonomy based approach
- Familial genetic risks: how can we better navigate patient confidentiality and appropriate risk disclosure to relatives?
- Risk-reducing decisions regarding germline BRCA pathogenic variant: focusing on the timing of genetic testing and RRSO
- Evaluation of BRCA1 and BRCA2 mutation prevalence, risk prediction models and a multistep testing approach in French-Canadian families with high risk of breast and ovarian cancer
- Disclosure ‘downunder’: misadventures in Australian genetic privacy law
- Medicolegal and insurance issues regarding BRCA1 and BRCA2 gene tests in high income countries